Position in SVRA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$11,530,875
+$1,464,575 QoQ
Shares Held
2,111,882
+26.5% QoQ
Ownership
1.03%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#24
of 184 holders
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 99.60045116157058.ToString("F0")%
Shared 0.ToString("F0")%
None 0.3995488384294198.ToString("F0")%
Common Shares in SVRA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026D. E. Shaw & Co., Inc. holds $4,382,181,531 across 180 Biotechnology names. SVRA ranks #59 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
5,625,825 | $919,934,903 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,059,062 | $350,411,843 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
2,545,486 | $189,027,789 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
2,865,318 | $166,503,628 | |
| 5 | EXEL |
Exelixis, Inc.
|
3,603,063 | $154,535,371 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
1,868,708 | $120,774,597 | |
| 7 | PTCT |
Ptc Therapeutics, Inc.
|
1,640,381 | $111,759,157 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
248,960 | $111,170,598 |
All Filings in SVRA
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,530,875 | 2,111,882 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $10,066,300 | 1,669,370 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $1,328,128 | 372,025 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $181,744 | 79,713 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $155,840 | 56,260 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $216,619 | 70,560 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $72,135 | 17,013 | Shares | Defined | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||